The MEA fluorescent immunoassay market is expected to grow from US$ 91.36 million in 2021 to US$ 109.74 million by 2028; it is estimated to grow at a CAGR of 2.7% from 2021 to 2028.
Human blood is an essential medical detection index. With the development of clinical medical detection instruments and detection technologies, the requirements for detection accuracy and efficiency have been gradually improved. Early diagnosis and complete surgical resection offer the best prospects for curative cancer treatment. Fluorescence immunochromatography is a new detection technique. It is characterized by high efficiency, convenience, no pollution, and a large detection area. Human blood can be rapidly detected using fluorescent immunochromatography. The concentration of pathogenic factors (cancer cells) in human serum can be conveniently and accurately measured. The system integrates many peripheral modules, including fluorescence signal acquisition, processing, quantitative curve fitting, and test results. The translation of laboratory science into effective clinical cancer therapy is growing significantly. Understanding cancer cell surface receptors, cancer cell growth, and cancer metabolic pathways have led to many promising molecularly targeted therapies and cancer gene therapies. In the laboratory setting, fluorescence imaging (FI) and bioluminescence imaging (BLI) has long been used in preclinical research to quantify tumor mass, assess tumor targeting by experimental drugs, and distinguish between primary and secondary effects of cancer treatments. Many cancers, including breast, colon, and skin cancer, spread to lymph nodes that have significant prognostic and therapeutic implications. Fluorescent dyes have long been used in this endeavor. The dye is injected near the primary tumor; fluorescence detection then identifies the first group of nodes to which the lymph travels. These lymph nodes are called sentinel lymph nodes and are biopsied because they are the most likely to have cancer. Therefore, the rising number of cancer cases worldwide and the growing need for early detection are expected to provide growth opportunities for the fluorescent immunoassays market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA fluorescent immunoassay market at a notable CAGR during the forecast period.
Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the MEA fluorescent immunoassay market.
Human blood is an essential medical detection index. With the development of clinical medical detection instruments and detection technologies, the requirements for detection accuracy and efficiency have been gradually improved. Early diagnosis and complete surgical resection offer the best prospects for curative cancer treatment. Fluorescence immunochromatography is a new detection technique. It is characterized by high efficiency, convenience, no pollution, and a large detection area. Human blood can be rapidly detected using fluorescent immunochromatography. The concentration of pathogenic factors (cancer cells) in human serum can be conveniently and accurately measured. The system integrates many peripheral modules, including fluorescence signal acquisition, processing, quantitative curve fitting, and test results. The translation of laboratory science into effective clinical cancer therapy is growing significantly. Understanding cancer cell surface receptors, cancer cell growth, and cancer metabolic pathways have led to many promising molecularly targeted therapies and cancer gene therapies. In the laboratory setting, fluorescence imaging (FI) and bioluminescence imaging (BLI) has long been used in preclinical research to quantify tumor mass, assess tumor targeting by experimental drugs, and distinguish between primary and secondary effects of cancer treatments. Many cancers, including breast, colon, and skin cancer, spread to lymph nodes that have significant prognostic and therapeutic implications. Fluorescent dyes have long been used in this endeavor. The dye is injected near the primary tumor; fluorescence detection then identifies the first group of nodes to which the lymph travels. These lymph nodes are called sentinel lymph nodes and are biopsied because they are the most likely to have cancer. Therefore, the rising number of cancer cases worldwide and the growing need for early detection are expected to provide growth opportunities for the fluorescent immunoassays market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA fluorescent immunoassay market at a notable CAGR during the forecast period.
MEA Fluorescent Immunoassay Market Segmentation
The MEA fluorescent immunoassay market is segmented into product type, application, end user, and country. Based on product type, the market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on application, the market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on country, the MEA fluorescent immunoassay market is segmented into South Africa, the UAE, Saudi Arabia, and the Rest of MEA.Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the MEA fluorescent immunoassay market.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Fluorescent Immunoassay Market - By Product Type
1.3.2 MEA Fluorescent Immunoassay Market - By Application
1.3.3 MEA Fluorescent Immunoassay Market - By End User
1.3.4 MEA Fluorescent Immunoassay Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Fluorescent Immunoassay Market - Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinions
5. MEA Fluorescent Immunoassay Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Chronic Diseases
5.1.2 Increasing Demand for Cell Therapies
5.2 Market Restraints
5.2.1 Disadvantages of Fluorescent Immunoassays
5.3 Market Opportunities
5.3.1 Extensive Usage in Cancer Diagnostics
5.4 Future Trends
5.4.1 Increase in Development of Fluorescent Dyes and Instruments
5.5 Impact Analysis
6. Fluorescent Immunoassay Market - MEA Analysis
6.1 MEA Fluorescent Immunoassay Marker Revenue Forecast and Analysis
7. MEA Fluorescent Immunoassay Market Analysis - By Product Type
7.1 Overview
7.2 MEA Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)
7.3 ELISA
7.3.1 Overview
7.3.2 ELISA: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
7.4 Rapid Lateral Flow Immunoassay
7.4.1 Overview
7.4.2 Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8. MEA Fluorescent Immunoassay Market Analysis - By Application
8.1 Overview
8.2 MEA Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)
8.3 Infectious Diseases
8.3.1 Overview
8.3.2 Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.4 Oncology
8.4.1 Overview
8.4.2 Oncology: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.5 Cardiovascular Disease
8.5.1 Overview
8.5.2 Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9. MEA Fluorescent Immunoassay Market Analysis - By End User
9.1 Overview
9.2 MEA Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)
9.3 Hospitals & Clinics
9.3.1 Overview
9.3.2 Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.4 Diagnostic Centers
9.4.1 Overview
9.4.2 Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.5 Pharmaceutical & Biotechnology Companies
9.5.1 Overview
9.5.2 Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.6 Academic & Research Institutes
9.6.1 Overview
9.6.2 Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Fluorescent Immunoassay Market Revenue and Forecast to 2028 (USD Million)
10. MEA Fluorescent Immunoassay Market Analysis - By Country
10.1 Overview
10.1.1 Middle East & Africa Fluorescent Immunoassay Market, by Country, 2021 & 2028 (%)
10.1.1.1 Saudi Arabia: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.1 Saudi Arabia: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.2 Saudi Arabia Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.3 Saudi Arabia Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.1.4 Saudi Arabia Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.2 UAE: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.1 UAE: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.2 UAE: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.3 UAE: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.2.4 UAE: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.3 South Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.1 South Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.2 South Africa Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.3 South Africa Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.3.4 South Africa Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
10.1.1.4 Rest of Middle East and Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.1 Rest of Middle East and Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.2 Rest of Middle East & Africa Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.3 Rest of Middle East & Africa: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
10.1.1.4.4 Rest of Middle East & Africa: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Thermo Fisher Scientific Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Abbott
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 BD
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Danaher
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 bioMerieux SA
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sysmex Corporation
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Siemens AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Ortho Clinical Diagnostics Holdings plc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Quidel Corporation
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
List of Figures
Figure 1. MEA Fluorescent Immunoassay Market Segmentation
Figure 2. MEA Fluorescent Immunoassay Market - By Country
Figure 3. MEA Fluorescent Immunoassay Market Overview
Figure 4. MEA Fluorescent Immunoassay Market, By Product Type
Figure 5. MEA Fluorescent Immunoassay Market, By Country
Figure 6. MEA PEST Analysis
Figure 7. MEA Fluorescent Immunoassay Market Impact Analysis of Driver and Restraints
Figure 8. MEA Fluorescent Immunoassay Market - Revenue Forecast and Analysis
Figure 9. MEA Fluorescent Immunoassay Market Share by Product Type - 2021 & 2028 (%)
Figure 10. MEA ELISA: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 11. MEA Rapid Lateral Flow Immunoassay: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 12. MEA Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 13. MEA Fluorescent Immunoassay Market Share by Application - 2021 & 2028 (%)
Figure 14. MEA Infectious Diseases: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 15. MEA Oncology: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 16. MEA Cardiovascular Disease: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 17. MEA Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 18. MEA Fluorescent Immunoassay Market Share by End User - 2021 & 2028 (%)
Figure 19. MEA Hospitals & Clinics: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 20. MEA Diagnostic Centers: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 21. MEA Pharmaceutical & Biotechnology Companies: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 22. MEA Academic & Research Institutes: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 23. MEA Others: Fluorescent Immunoassay Market Revenue and Forecasts To 2028 (USD Million)
Figure 24. Middle East & Africa: Fluorescent Immunoassay Market, by Key Country - Revenue (2021) (USD Million)
Figure 25. Middle East & Africa: Fluorescent Immunoassay Market, by Country, 2021 & 2028 (%)
Figure 26. Saudi Arabia: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
Figure 27. UAE: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
Figure 28. South Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)
Figure 29. Rest of Middle East and Africa: Fluorescent Immunoassay Market - Revenue and Forecast to 2028 (USD Million)List of Tables
Table 1. MEA Fluorescent Immunoassay Market -Revenue and Forecast to 2028 (USD Million)
Table 2. Saudi Arabia Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 3. Saudi Arabia Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 4. Saudi Arabia Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 5. UAE: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 6. UAE: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 7. UAE: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 8. South Africa Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 9. South Africa Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million
Table 10. South Africa Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 11. Rest of Middle East & Africa: Fluorescent Immunoassay Market, by Product Type - Revenue and Forecast to 2028 (USD Million)
Table 12. Rest of Middle East & Africa: Fluorescent Immunoassay Market, by Application - Revenue and Forecast to 2028 (USD Million)
Table 13. Rest of Middle East & Africa: Fluorescent Immunoassay Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 14. Organic Developments
Table 15. Inorganic Developments
Table 16. Glossary of Terms
Companies Mentioned
- Abbott
- BD
- bioMerieux SA
- Danaher
- F. Hoffmann-La Roche Ltd.
- Ortho Clinical Diagnostics Holdings plc
- Quidel Corporation
- Siemens AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 157 |
| Published | August 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 91.36 Million |
| Forecasted Market Value ( USD | $ 109.74 Million |
| Compound Annual Growth Rate | 2.7% |
| Regions Covered | Africa, Middle East |
| No. of Companies Mentioned | 10 |
